WHC is still in active development. Read this to understand our approach.
depiction of HNDVDQJCIGZPNO-UHFFFAOYSA-N.svg
isomerdesign

2-Amino-3-(1H-imidaz...

Check on isomerdesign

pubchem

Histidine

Check on pubchem

drugmap

[14C]histidine

Check on drugmap

drugmap

[14C]histidine

Check on drugmap

Data

InChI: InChI=1S/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)

Synonyms: CCG-204656,L-Histidine, Cell Culture Reagent,HISTIDINE [WHO-DD],(S)-2-Amino-3-(4-imidazolyl)propionic acid,(S)-a-Amino-1H-imidazole-4-propanoate,NSC-137773,NCGC00015518-01,AI3-26558,Histidine (L-Histidine),Histidinum [INN-Latin],F8889-0575,H-2310,his,US9138393, Histidine,SCHEMBL3259,[3H]histidine,HISTIDINE [MI],EINECS 200-745-3,GTPL3310,4QD397987E,L-Histidine, cell culture tested, meets EP, USP testing specifications, from non-animal source,CHEMBL17962,CS-7781,AC-35086,1lag,histidina,ZINC6661227,HISTIDINE [HSDB],(S)-alpha-amino-1H-imidazole-4-propanoic acid,(2S)-2-amino-3-(1H-imidazol-4-yl)propanoic acid,SDCCGSBI-0050549.P002,1H-Imidazole-4-alanine, (S)-,BDBM7953,D00032,L-Histidine, certified reference material, TraceCERT(R),2-Amino-3-(1H-imidazol-4-yl)propanoic acid,Histidine, monohydrochloride,(2S)-2-amino-3-(imidazol-4-yl)propanoic acid,DB00117,L-beta-(4-Imidazolyl)-alpha-alanin,AKOS015854051,(2S)-2-amino-3-(1H-imidazol-4-yl)propanoic acid hydrochloride,HISTIDINE [II],amino-1H-imidazole-4-propanoate,L-Histidine (JP17),Histidina [INN-Spanish],glyoxaline-5-alanine,3-(1H-imidazol-4-yl)-L-Alanine,(S)-1H-Imidazole-4-alanine,HISTIDINE [INN],L-His,HISTIDINE, L-,US9144538, Histidine,L-HISTIDINE [USP-RS],Z359369984,amino-4-imidazoleproprionate,[3H]-histidine,H-His-OH,S-Histidine,L-HISTIDINE [FCC],AS-14171,Lopac-H-8125,D70843,L-Histidine, Pharmaceutical Secondary Standard; Certified Reference Material,L-HISTIDINE [JAN],HISTIDINE [USAN],(S)1H-Imidazole-4-alanine,F8881-8926,alpha-Amino-4(or 5)-imidazolepropionic acid,(S)-a-Amino-1H-imidazole-4-propanoic acid,Histidine,(S),NCGC00162189-01,064H315,MFCD00064315,(S)-2-Amino-3-(4-imidazolyl)propionsaeure,7006-35-1,H0149,L-Alanine, 3-(1H-imidazol-4-yl)-,L-Histidine, Vetec(TM) reagent grade, >=99%,BDBM181118,NCGC00162189-02,L-Histidine (H-His-OH),HY-N0832,HISTIDINE [MART.],Histidinum,L-(-)-Histidine,L-Histidin,1H-Imidazole-4-propanoic acid, .alpha.-amino-, (S)-,(S)-alpha-Amino-1H-imidazole-4-propionate,(S)-2-amino-3-(1H-imidazol-4-yl)propanoic acid,AKOS026676613,NCGC00162189-05,L-Histidine, BioUltra, >=99.5% (NT),L-Histidine, ReagentPlus(R), >=99% (TLC),L-2-Amino-3-(4-imidazolyl)propionic acid,UNII-4QD397987E,(S)-4-(2-Amino-2-carboxyethyl)imidazole,HISTIDINE [VANDF],L-Histidine, p.a., 98.5%,bmse000039,L-Histidine, United States Pharmacopeia (USP) Reference Standard,HISTIDINE [USP MONOGRAPH],71-00-1,amino-1H-imidazole-4-propanoic acid,S3989,Histidine (USP/INN),[14C]-histidine,alpha-Amino-1H-imidazole-4-propionic acid, (S)-,HSDB 1810,AM81801,EN300-57334,Imidazole C-4(5) deriv. 5,L-histidine,L-Histidine, PharmaGrade, Ajinomoto, EP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture,(S)-Histidine,4-(2-Amino-2-carboxyethyl)imidazole,GTPL4670,(S)-alpha-Amino-1H-imidazole-4-propanoate,Histidine, European Pharmacopoeia (EP) Reference Standard,HISTIDINE [EP MONOGRAPH],L-HISTIDINE [FHFI],amino-4-imidazoleproprionic acid,CHEBI:15971,(2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid,C00135,Histidine,Histidine [USAN:INN],L-beta-(4-Imidazolyl)alanin,Q485277,B81AEDB0-EACA-4296-9BAB-52D60F137FFB,DTXSID9023126,histidine,bmse001015,Lopac0_000566,Anti-rheuma,NSC 137773,Histidine (VAN),Istidina,M02982,(S)-alpha-Amino-1H-imidazole-4-propionic acid,1H-Imidazole-4-propanoic acid, alpha-amino-, (S)-,L-Histidine, non-animal source,1hsl,L-Histidine, SAJ special grade, >=98.5%,SERINE IMPURITY C [EP IMPURITY],FEMA No. 3694,L-Hisidine,HISTIDINE [INCI],bmse000976,(L)-Histidine,L-hystidine


Estimated data

Solubility: -0.389 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 34.1% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.